meropenem – therapeutic recommendation after twenty years of presence on pharmaceutical market
Clicks: 232
ID: 143040
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
232 views
50 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #16 of 41 articles by views in voprosy pitaniia
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Meropenem is the first representative of carbapenem analogues with methyl group, which has been applied in medicine. This drug has been approved by FDA (Food and Drug Administration) in 1996. Available results of clinical trials and scientific reports point surprising synergism of combination of meropenem with other chemotherapeutics, in the treatment of bacterial diseases. Present study based on available information presents indications for use the mentioned antibiotic in pharmacotherapy of infectious diseases. Meropenem is the first representative of carbapenem analogues, which contains methyl group. Introduction of a methyl group at the system of coupled rings: β-lactam and pyrrolidine, solved the problem of degradation by the dehydropeptidase-I (DHP-I). In the consequence it is not necessary to use meropenem in the connection with specific DHP-I inhibitors. Meropenem, similarly to other carbapanem analogues, is intended for the treatment of severe inpatient and outpatient infections. Bacterial resistance to meropenem may be the result of: carbapenemases activity, decreased affinity to Penicillin Binding Proteins - PBP (mainly PBP 2 and PBP 3) and activation of efflux pump (antibiotic ejection outside the cell). Twenty-year period of application of meropenem in pharmacotherapy may cause the spread of methyl-β-lactamases.
| Reference Key |
paczkowska2014postpymeropenem
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Magdalena Paczkowska;Piotr Garbacki;Przemysław Zalewski;Alicja Talaczyńska;Judyta Cielecka-Piontek |
| Journal | voprosy pitaniia |
| Year | 2014 |
| DOI |
10.5604/01.3001.0003.1221
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.